CINV Existing and Pipeline Drugs Market Size, Share, Growth, Trends and Industry Analysis, By Type (Aloxi, Zofran Generic, Kytril Generic, Emend, Akynzeo, SUSTOL, Rolapitant), By Application (Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies, Drugstores), Regional Insights and Forecast From 2025 to 2034

• 

  Request a Free sample to learn more about this report

CINV EXISTING AND PIPELINE DRUGS MARKET OVERVIEW

The global cinv existing and pipeline drugs market size is estimated at USD 1.59 billion in 2025 and expected to rise to USD 2.14 billion by 2034, experiencing a CAGR of 3.31% during the forecast period from 2025 to 2034.

The United States CINV Existing and Pipeline Drugs market size is projected at USD 0.5 billion in 2025, the Europe CINV Existing and Pipeline Drugs market size is projected at USD 0.4 billion in 2025, and the China CINV Existing and Pipeline Drugs market size is projected at USD 0.49 billion in 2025.

CINV significantly impacts the quality of life for cancer patients. The existing market offers antiemetic drugs such as 5-HT3 receptor antagonists, NK1 receptor antagonists, and corticosteroids, effectively managing CINV. However, the evolving landscape witnesses a promising pipeline with novel agents like neurokinin-1 receptor inhibitors, ghrelin receptor agonists, and cannabinoid receptor agonists. These innovative drugs aim to enhance efficacy, reduce side effects, and address unmet needs in CINV management. As the market expands, the quest for improved therapeutic options persists, fostering optimism for advancing cancer care and alleviating the burden of treatment-related nausea and vomiting.

KEY FINDINGS

COVID-19 IMPACT

Market Growth Restrained by Pandemic Due to Supply Chain Disruptions

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to market’s growth and demand returning to pre-pandemic levels.

The COVID-19 pandemic has presented challenges to the existing and pipeline drugs market for CINV. Disruptions in healthcare services, lockdowns, and resource reallocations have hindered patient access to chemotherapy, impacting the prevalence of CINV cases. Furthermore, clinical trials and drug development faced delays due to pandemic-related restrictions, affecting the progression of novel CINV treatments. Economic uncertainties and healthcare system strains also influenced market dynamics, affecting product adoption and CINV existing and pipeline drugs market growth. Despite setbacks, the industry adapts with resilience, striving to mitigate negative impacts and advance CINV management to ensure continued progress in cancer patient care.

LATEST TRENDS

Increasing Focus on Personalized Medicine Helps Market Grow

Amidst the landscape of CINV management, a notable trend emerges as pharmaceutical companies increasingly focus on personalized medicine. Tailoring antiemetic treatments based on individual patient profiles and genetic markers represents a paradigm shift, aiming for enhanced efficacy and reduced side effects. This personalized approach not only reflects a commitment to precision medicine but also signifies a significant stride towards optimizing the therapeutic outcomes for cancer patients experiencing CINV. As the industry embraces this trend, it holds the potential to reshape the CINV treatment landscape, offering more targeted and efficient solutions in the near future.

• According to the U.S. National Cancer Institute (NCI), over 1.9 million new cancer cases were diagnosed in the U.S. in 2023, with nearly 80% of patients undergoing chemotherapy reporting symptoms of nausea and vomiting, driving demand for advanced antiemetic drugs.

• As per the European Medicines Agency (EMA), 6 novel pipeline drugs targeting CINV entered Phase II or III clinical trials in 2023 across Europe, reflecting a trend toward multi-receptor antagonists for better emetic control.

Request a Free sample to learn more about this report

CINV EXISTING AND PIPELINE DRUGS MARKET SEGMENTATION

By Type

Based on type the global market can be categorized into aloxi, zofran generic, kytril generic, emend, akynzeo, sustol, rolapitant

• ALOXI: A drug known for its effectiveness in preventing and treating chemotherapy-induced nausea and vomiting by targeting serotonin receptors.

• Zofran Generic: Generic formulations of Zofran, a widely used antiemetic that inhibits serotonin signaling, providing relief for CINV.

• Kytril Generic: Generic versions of Kytril, a 5-HT3 receptor antagonist, utilized to manage nausea and vomiting induced by chemotherapy.

• Emend: A neurokinin-1 (NK1) receptor antagonist offering a targeted approach to CINV by blocking signals in the central nervous system

• Akynzeo: A combination drug containing netupitant and palonosetron, addressing both acute and delayed phases of CINV by targeting multiple pathways.

• Sustol: A sustained-release granisetron formulation providing prolonged control of nausea and vomiting during and after chemotherapy.

• Rolapitant: A substance Pneurokinin-1 receptor antagonist used to prevent delayed-phase chemotherapy-induced nausea and vomiting.

By Application

Based on application the global market can be categorized into hospitals, specialty clinics, diagnostic centers therapeutics, hospital pharmacies, drugstores

• Hospitals: Utilizing CINV drugs in the hospital setting involves administering antiemetic medications to cancer patients undergoing chemotherapy to alleviate nausea and vomiting.

• Specialty Clinics: Specialized medical facilities focused on oncology may administer CINV drugs to cancer patients undergoing chemotherapy as part of their comprehensive treatment plan.

• Diagnostic Centers: CINV drugs may be employed in diagnostic centers to address and manage the nausea and vomiting associated with chemotherapy administered during cancer diagnostic procedures.

• Therapeutics: In therapeutic settings, CINV drugs are integral to managing and improving the overall well-being of patients by effectively addressing the adverse effects of chemotherapy.

• Hospital Pharmacies: Hospital pharmacies play a crucial role in dispensing CINV medications, ensuring timely access to antiemetic drugs for cancer patients undergoing chemotherapy within hospital premises.

• Drugstores: Drugstores provide community-based access to CINV drugs, allowing patients to obtain prescribed antiemetic medications for at-home use, facilitating continued management of chemotherapy-induced nausea and vomiting.

DRIVING FACTORS

Advancements in Targeted Therapies Drives the Market

The evolution of targeted therapies for cancer, characterized by precision medicine and personalized treatment approaches, stands as a key driving factor for the CINV drugs market. As oncology research continues to unravel molecular intricacies, drug developers are leveraging this knowledge to design antiemetic medications tailored to specific cancer types and patient profiles. This shift towards targeted therapies not only enhances treatment efficacy but also addresses the unique challenges posed by different chemotherapy regimens, fostering a more nuanced and effective management of CINV.

Growing Focus on Patient-Centric Solutions Drives the Market

A pivotal driver in the CINV drugs market is the increasing emphasis on patient-centric care. Recognizing the profound impact of CINV on the quality of life for cancer patients, pharmaceutical companies are prioritizing the development of drugs that not only effectively manage nausea and vomiting but also minimize adverse effects, thereby improving overall patient well-being. This patient-centered approach extends beyond efficacy to factors such as convenience of administration, reduced treatment burden, and enhanced compliance, reflecting a comprehensive commitment to optimizing the holistic experience of individuals undergoing chemotherapy.

• According to the World Health Organization (WHO), global chemotherapy usage increased by 37% between 2017 and 2023, significantly boosting the need for supportive therapies like antiemetic agents to manage CINV.

• The U.S. FDA reported in 2023 that 5 new anti-nausea drugs were granted fast-track or breakthrough therapy designations due to strong efficacy against delayed-phase CINV in breast and lung cancer patients.

RESTRAINING FACTORS

Clinical Trial Delays and Regulatory Challenges Restrains the Market

One significant restraining factor impeding the CINV drugs market is the inherent complexity of conducting clinical trials and navigating regulatory processes. Stringent regulatory requirements, coupled with the need for extensive testing to ensure safety and efficacy, often lead to prolonged timelines for drug development and market entry. Delays in obtaining regulatory approvals can impede the availability of new and potentially more effective CINV treatments, limiting the timely introduction of innovations into clinical practice. As the industry grapples with these challenges, streamlining regulatory pathways and expediting clinical trial processes become imperative for accelerating advancements in CINV drug development.

• As per the National Institutes of Health (NIH), nearly 22% of oncology patients discontinue or skip antiemetic medication due to side effects such as constipation, dizziness, or fatigue, impacting adherence.

• According to the UK’s National Institute for Health and Care Excellence (NICE), CINV drug costs per treatment cycle increased by 28% from 2018 to 2023, leading to affordability concerns among lower-income patient groups and public healthcare systems.

• Request a Free sample to learn more about this report

•  

CINV EXISTING AND PIPELINE DRUGS MARKET REGIONAL INSIGHTS

North America to Lead the Market Due to Advanced Healthcare Infrastructure

The market is primarily segregated into Europe, Latin America, Asia Pacific, North America, and Middle East & Africa.

The dominance in the CINV existing and pipeline drugs market share is likely to be influenced by North America. This region is expected to play a significant role due to factors such as advanced healthcare infrastructure, substantial research and development activities, and a high prevalence of cancer cases. Additionally, the presence of major pharmaceutical companies and a well-established regulatory framework contribute to the prominence of North America in shaping the trajectory of CINV drug development. However, it's essential to note that the global nature of the pharmaceutical industry means that contributions from other regions, particularly Europe and Asia, will also play crucial roles in the overall market dynamics.

KEY INDUSTRY PLAYERS

Key Industry Players Shaping the Market Through Innovation and Market Expansion

Leading the charge in CINV drug development are key industry players such as Merck & Co., Helsinn Group, Eisai, GlaxoSmithKline (via Tesaro acquisition), and Heron Therapeutics. Renowned for their commitment to oncology research, Merck & Co. emphasizes precision medicine, while Helsinn Group focuses on supportive care. Eisai adopts a comprehensive cancer care approach, and GlaxoSmithKline, post-Tesaro acquisition, leverages a broader pharmaceutical reach. Heron Therapeutics stands out for its innovative sustained-release formulations. Collectively, these industry leaders drive market innovation, expanding their global footprint to enhance CINV treatment efficacy and patient outcomes.

• GlaxoSmithKline (U.K.): According to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), GlaxoSmithKline’s CINV drug Ondansetron accounted for over 6.2 million prescriptions in the U.K. between 2020 and 2023, making it one of the most widely used 5-HT3 antagonists for chemotherapy support.

• Helsinn (Switzerland): Based on data from Swissmedic (Swiss Agency for Therapeutic Products), Helsinn’s AKYNZEO (netupitant/palonosetron) was approved in over 68 countries by 2023, and has been administered to more than 3.5 million cancer patients globally for the prevention of acute and delayed CINV.

List of Top CINV Existing and Pipeline Drugs Companies 

• GlaxoSmithKline (U.K.)
• Helsinn (Switzerland)
• Heron Therapeutics (U.S.)
• Merck (known as MSD outside North America) (U.S.)
• Tesaro (acquired by GlaxoSmithKline) (U.K.)

INDUSTRIAL DEVELOPMENT

October 2022: An industrial development in the CINV market is the introduction of innovative NK1 receptor antagonists. These next-generation drugs, designed to target the neurokinin-1 receptor associated with nausea and vomiting, represent a significant leap forward in CINV treatment. With enhanced efficacy and reduced side effects compared to traditional therapies, these novel antagonists demonstrate the industry's commitment to refining and optimizing antiemetic strategies. The development and integration of such advanced agents into the existing CINV drug landscape signal a promising shift towards more targeted and efficient solutions for patients undergoing chemotherapy.

REPORT COVERAGE

The CINV market reflects a dynamic landscape driven by continuous innovation and a commitment to enhancing patient outcomes. Key industry players, including Merck & Co., Helsinn Group, Eisai, GlaxoSmithKline, and Heron Therapeutics, are spearheading advancements through precision medicine, supportive care approaches, and sustained-release formulations. The emergence of novel NK1 receptor antagonists signifies a cutting-edge industrial development, offering more targeted and effective solutions. Despite challenges such as clinical trial delays, the industry's resilience remains evident. As the market evolves, the focus on personalized medicine and patient-centric care positions CINV treatment on a trajectory of constant improvement, promising better quality of life for cancer patients.